Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Advani, Anjali S ^a   Gibson, Sarah E ^b   Douglas, Elizabeth ^b   Jin, Tao ^b   Zhao, Xiaoxian ^b   Kalaycio, Matt ^a   Copelan, Ed ^a   Sobecks, Ronald ^a   Sekeres, Mikkael ^a   Sungren, Shawnda ^a   Hsi, Eric D ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; HISTONE H3; HISTONE H4; IMATINIB; MITOXANTRONE; PREDNISONE; VINCRISTINE; BUTYRIC ACID DERIVATIVE; HISTONE;

ACETYLATION; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE; ALLOTRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOGENETICS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; OVERALL SURVIVAL; PROGNOSIS; RISK ASSESSMENT; ADOLESCENT; BIOPSY; BONE MARROW; CELL CULTURE; DRUG EFFECT; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY; REMISSION; SURVIVAL RATE; TUMOR RECURRENCE; WESTERN BLOTTING;

ACETYLATION; ADOLESCENT; ADULT; BIOPSY; BLOTTING, WESTERN; BONE MARROW; BUTYRATES; CELLS, CULTURED; HISTONES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; YOUNG ADULT;

EID: 77954683659     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-387     Document Type: Article

References (15)

1. Hadnagy A, Beaulieu R, Balicki D. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Mol Cancer Ther 2008, 7:740-748. 10.1158/1535-7163.MCT-07-2284, 18413789.
2. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. Journal of Clinical Oncology 2007, 25:4051-4056. 10.1200/JCO.2007.11.6202, 17827453.
3. de Ruijter A, Gennip A, Caron H, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003, 370:737-749. 10.1042/BJ20021321, 1223209, 12429021.
4. Thiagalingam S, Cheng K, Lee H, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: Unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003, 983:84-100. 10.1111/j.1749-6632.2003.tb05964.x, 12724214.
5. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004, 101:1241-1246. 10.1073/pnas.0307708100, 337037, 14734806.
6. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 2001, 7:962-970.
7. Toh Y, Ohga T, Endo K, Adachi E, Kusumoto H, Haraguchi M, Okamura T, Nicolson GL. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. International Journal of Cancer 2004, 110:362-367.
8. Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM, Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Research and Treatment 2005, 90:15-23. 10.1007/s10549-004-1668-2, 15770522.
9. Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, Pettenati MJ, Le Beau MM, Frankel SR, Stewart CC, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999, 93:3983-3993.
10. Hoelzer D, Theil E, Loffler H, Buchner T, Ganser A, Heil G, Koch P, Freund M, Diedrich H, Ruhl H. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988, 71:123-131.
11. Hoelzer D, Goekbuget N. Acute lymphoblastic leukemia in adults. Leukemia 2002, 621-656. New York: Saunders, Henderson E, Lister TA, Greaves MF.
12. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, Hooberman AL, Westbrook CA, Arthur DC, George SL, Bloomfield CD, Schiffer CA. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B 8111. Blood 1995, 85:2025-2037.
13. Stock W, Johnson J, Yu D, Bennett D, Sher D, Stone RM, Kolitz JE, Powell BL, Wetzler M, Vardiman JC, Bloomfield CD, Larson RA. Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia (ALL): final results from CALGB 19802. American Society of Hematology 2005, Atlanta, GA, December 10-13. Abstract 833..
14. Weiss MA, Heffner L, Lamanna N, Kalaycio M, Schiller G, Coutre S, Maslak P, Jurcic J, Panageas K, Scheinberg DA. A randomized trial demonstrating the superiority of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy in patients with acute lymphoblastic leukemia. American Society of Clinical Oncology 2005, Orlando, FL, May 13-17. Abstract 6516. .
15. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266. 10.1038/nature03672, 15988529.